BridgeBio Oncology Therapeutics (BBOT) earnings
In the quarter ended June 2026, BridgeBio Oncology Therapeutics had revenue of —, and diluted EPS of -705.20.
On August 11, 2026 it reported EPS of -0.71 against an estimate of -0.55 (missed).
The next report is expected on Wednesday, November 11, 2026, with EPS expected around -0.65.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Wed Nov 11, 2026 | — | -0.65 | — |
| Last | Tue Aug 11, 2026 | After close | -0.55 | -0.71 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 10 quarters from BridgeBio Oncology Therapeutics's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | — | — | -705.20 | — | — | 2026-08-11 |
| Mar 31, 2026 | — | — | -526.11 | — | — | 2026-05-12 |
| Dec 31, 2025 | — | — | — | — | — | 2026-03-05 |
| Sep 30, 2025 | — | — | -1.03 | — | — | 2025-11-12 |
| Jun 30, 2025 | — | — | -566.46 | — | — | 2025-08-01 |
| Mar 31, 2025 | — | — | -54.23 | — | — | 2025-05-15 |
| Dec 31, 2024 | — | — | — | — | — | 2025-03-11 |
| Sep 30, 2024 | — | — | -1562.18 | — | — | 2024-11-14 |
| Jun 30, 2024 | — | — | — | — | — | 2024-08-14 |
| Mar 31, 2024 | — | — | — | — | — | 2024-05-15 |
Questions
When does BridgeBio Oncology Therapeutics report earnings?
BridgeBio Oncology Therapeutics's next earnings report is expected on November 11, 2026.
How did BridgeBio Oncology Therapeutics do last quarter?
In the quarter ended June 2026, BridgeBio Oncology Therapeutics had revenue of —, and diluted EPS of -705.20.
From BridgeBio Oncology Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.